CEO & founder @ Darmiyan a lens into the human brain using non-invasive brain scan (MRI) + virtual microscope (novel technology developed @ Darmiyan) + AI
Congrats to #Darmiyan, a CABHI-portfolio company, on launching the BrainSee platform for Alzheimer’s testing! Darmiyan’s received early funding from CABHI, powered by @Baycrest, to support its innovation journey.
Read more ➡️ https://t.co/NzmU0R3YhJ
FDA-approved breakthrough Alzheimer's test BrainSee now available nationwide through BrainSee platform and BrainSee patient portal https://t.co/z5z3MRofEd
{Fighting Stigma} Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for Alzheimer's Testing: ... Alzheimer's disease. This innovative platform is designed to ... Athira's Small Molecule Injection for Alzheimer's Flops in Phase II/III… https://t.co/g12sfmlfwa
Latest on #Alzheimers: https://t.co/pApNGV0eIs Darmiyan introduces Alzheimer’s testing platform with BrainSee test - Medical Device Network #Alzheimer... #Alzheimeric
New in our #SFBay newsletter: BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research; Darmiyan, Inc. Announces Launch of Groundbreaking BrainSee Platform for #Alzheimers Testing
For more updates, subscribe here: https://t.co/ZjFGhF3p8K
Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer's Dementia https://t.co/ByUCWhpT0o
🚀 Groundbreaking in AI and healthcare! FDA approves BrainSee by Darmiyan, a pioneering AI tool for predicting cognitive decline towards Alzheimer's. This marks a significant stride in proactive disease management and patient care. 🧠💡
#AIHealthcare#InnovativeDiagnostics #BrainSee
Read more on Engadget:(https://t.co/gF8fiXkbQu).
Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer's Dementia https://t.co/ByUCWhpT0o
Congrats to the @DarmiyanInc (YC S17) team on the FDA approval of BrainSee!
https://t.co/sLBPXNUTHd
BrainSee can read a standard brain MRI scan and predict a patient’s chances of progressing from mild cognitive impairment to Alzheimer’s disease and dementia within five years.
Congratulations to @DarmiyanTech, winner of the 2019 CABHI Innovation Award, and @CatalystPharm, winner of the 2019 CABHI People’s Choice Award! Thanks to all who participated in our Pitch Competition. #CABHIinnovates
We are excited to announce that GERAS has partnered with @DarmiyanTech (winner of the 2019 CABHI Innovation Award), @Baycrest, and the @UHN to assess a new MRI Image platform for early detection of Alzheimer’s Disease! This project is funded by @CABHI__ I2P2